US Stock MarketDetailed Quotes
SCNI Scinai Immunotherapeutics
- 5.101
- -0.789-13.40%
Trading Jul 16 09:42 ET
4.28MMarket Cap-318P/E (TTM)
5.600High5.029Low205.70KVolume5.310Open5.890Pre Close1.09MTurnover28.15%Turnover RatioLossP/E (Static)838.58KShares14.20052wk High-0.94P/B3.73MFloat Cap2.23052wk Low--Dividend TTM730.73KShs Float6199.990Historical High--Div YieldTTM9.69%Amplitude2.230Historical Low5.286Avg Price1Lot Size
Scinai Immunotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -282.98%-1.46M | -29.14%-9.38M | -106.58%-1.23M | -16.82%-2.22M | -85.28%-5.55M | 65.43%-382K | 2.17%-7.27M | 67.91%-593K | 1.01%-1.9M | -23.36%-3M |
| Net income from continuing operations | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -1.63%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | -0.49%-3.7M |
| Operating gains losses | ---96K | ---4.14M | ---216K | ---591K | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 13.04%156K | -8.54%514K | -54.35%84K | 46.46%145K | -34.40%147K | 2.99%138K | 19.32%562K | 294.67%184K | -47.91%99K | 20.78%224.07K |
| Other non cash items | 169.66%225K | 110.27%401K | -73.12%770K | 32.50%-4.69M | 1,308.71%4.64M | -236.29%-323K | -23.86%-3.9M | 217.14%2.87M | -1,140.87%-6.95M | -340.56%-384.21K |
| Change In working capital | -43.44%220K | -393.73%-796K | -98.70%14K | -158.79%-427K | -256.66%-772K | -24.32%389K | -61.51%271K | 220.64%1.08M | -134.98%-165K | 345.67%492.79K |
| -Change in receivables | 6.43%149K | -307.14%-290K | -572.73%-208K | -373.68%-90K | -2,595.95%-132K | 13.82%140K | 137.29%140K | -67.94%44K | -105.04%-19K | 99.27%-4.9K |
| -Change in payables and accrued expense | -73.08%70K | -466.42%-491K | -78.45%223K | -128.57%-336K | 40.85%-638K | -33.33%260K | -79.29%134K | 338.88%1.04M | -839.61%-147K | -641.10%-1.08M |
| -Change in other current assets | 516.67%75K | -71.90%43K | -65.03%57K | --2K | --2K | -128.57%-18K | 3.38%153K | --163K | --0 | ---- |
| -Change in other current liabilities | -1,157.14%-74K | 62.82%-58K | 65.06%-58K | -400.00%-3K | -100.25%-4K | 111.29%7K | -4.00%-156K | 88.25%-166K | -98.66%1K | 169.83%1.58M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 52.17%-1.46M | -29.14%-9.38M | -106.58%-1.23M | -16.82%-2.22M | 4.04%-2.88M | -176.83%-3.06M | 2.17%-7.27M | 67.91%-593K | 1.01%-1.9M | -23.36%-3M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 66.67%-2K | 23.80%-637K | 13.33%-234K | 75.00%-20K | -1,458.29%-377K | 98.85%-6K | -501.44%-836K | -153.78%-270K | -1,881.57%-80K | 26.39%-24.19K |
| Net PPE purchase and sale | 66.67%-2K | 23.80%-637K | 13.33%-234K | 75.00%-20K | -2,874.92%-377K | 98.85%-6K | -501.44%-836K | -175.49%-270K | -6,340.10%-80K | 61.08%-12.67K |
| Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -3,650.85%-11.52K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 66.67%-2K | 23.80%-637K | 13.33%-234K | 75.00%-20K | -1,458.29%-377K | 98.85%-6K | -501.44%-836K | -153.78%-270K | -1,881.57%-80K | 26.39%-24.19K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 1.42M | -83.97%1.09M | 0 | 0 | -68.38%6.78M | -23.41%6.78M | -38.44%-134.79K | |||
| Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 5.34%-92.16K |
| Net common stock issuance | ---- | -85.09%139K | ---- | ---- | ---- | ---- | -95.65%932K | ---- | ---- | --0 |
| Proceeds from stock option exercised by employees | --1.42M | -83.80%947K | -102.38%-139K | ---- | ---- | --0 | --5.84M | --5.84M | ---- | --0 |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---42.63K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --1.42M | -83.97%1.09M | --0 | --1.09M | --0 | --0 | -68.38%6.78M | -23.41%6.78M | --0 | -38.44%-134.79K |
| Net cash flow | ||||||||||
| Beginning cash position | -64.76%5.01M | -18.85%14.22M | -23.24%6.48M | -33.19%7.63M | -22.40%10.93M | -18.85%14.22M | 469.29%17.52M | -21.55%8.45M | -13.46%11.42M | -5.63%14.08M |
| Current changes in cash | 98.56%-44K | -574.19%-8.93M | -124.66%-1.46M | 41.93%-1.16M | -3.07%-3.25M | -88.50%-3.07M | -109.56%-1.33M | -14.11%5.92M | 34.72%-1.99M | -23.30%-3.16M |
| Effect of exchange rate changes | --0 | 86.24%-272K | 90.73%-14K | 100.71%7K | -109.06%-41K | 37.60%-224K | -443.83%-1.98M | 48.68%-151K | -260.76%-987K | 509.21%452.47K |
| End cash Position | -54.55%4.97M | -64.76%5.01M | -64.76%5.01M | -23.24%6.48M | -32.91%7.63M | -29.65%10.93M | -18.85%14.22M | -18.85%14.22M | -21.55%8.45M | -7.13%11.38M |
| Free cash flow | 52.20%-1.47M | -23.68%-10.02M | -69.06%-1.46M | -13.12%-2.24M | -8.08%-3.25M | -88.50%-3.07M | -7.09%-8.1M | 55.66%-863K | -3.09%-1.98M | -22.24%-3.01M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
